Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development of Validated Stability Indicating HPTLC Method for the Estimation of Teriflunomide in Bulk and Tablet Dosage Form

Author(s): Snehal Karmankar* and M. Tajne

Volume 16, Issue 7, 2020

Page: [814 - 822] Pages: 9

DOI: 10.2174/1573412915666190320151500

Price: $65

Abstract

Background: Teriflunomide is an immunosuppressive agent. Immunosuppressive agents are drugs that inhibit or prevent activity of immune system. Teriflunomide was investigated as a medication for multiple sclerosis (MS). Various studies have reported the HPLC, UPLC, LC/MS methods for the estimation of teriflunomide. However, till date stability indicating HPTLC analysis method has not been reported for the estimation of teriflunomide in bulk and tablet dosage form.

Objective: Objective of the present work was to develop and validate stability indicating high performance thin layer chromatography method for the determination of teriflunomide in bulk and tablet dosage form.

Methods: Chromatography was performed on aluminium plates coated with silica gel 60F254 using toluene, methanol and acetic acid (7.5: 2.5: 0.05 v/v/v) as mobile phase. Densitometric analysis was performed at 254 nm. The method was validated with different parameters such as linearity, precision, accuracy, specificity, robustness, limit of detection (LOD) and limit of quantitation (LOQ). The RF value of teriflunomide was 0.56 ± 0.03. The method is sensitive (limit of quantification 17.83 ng/band), precise (RSD ≤ 1.34%), accurate (drug recovery 98.49–99.53 %), and linear over the range 100–600 ng/band (r2 0.998).

Results: Degradation products were found in stress conditions did not interfere with the detection of teriflunomide; therefore, the proposed technique can be considered stability-indicating. Teriflunomide did not degrade under alkaline hydrolysis, thermal and photolytic conditions but showed degradation under acid hydrolysis and oxidation with about 14.5 and 13.8 % decompositions respectively.

Conclusion: The developed method was satisfactorily applied for the analysis of pharmaceutical preparations and proved to be specific and accurate for quality control of the cited drugs in their tablet dosage form.

Keywords: HPTLC, teriflunomide, stability indicating, validation, degradation products, Multiple Sclerosis (MS).

« Previous Next »
Graphical Abstract

[1]
Riccio, P.; Rossano, R. Nutrition facts in multiple sclerosis. ASN Neuro, 2015, 7(1), 1-20.
[PMID: 25694551]
[2]
Freedman, M.S. Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Ther. Adv. Chronic Dis., 2013, 4(5), 192-205.
[PMID: 23997924]
[3]
Marriott, J.J.; O’Connor, P.W. Emerging therapies in relapsingremitting multiple sclerosis. Rev. Recent Clin. Trials, 2010, 5(3), 179-188.
[PMID: 20500147]
[4]
Warnke, C; Meyer zu Hörste, G; Hartung, HP; Stüve, O; Kieseier, BC Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat., 2009, 5, 333-40.
[5]
european public assessment report, aubagio (international nonproprietary name: teriflunomide), procedure no. emea/h/c/002514/0000. european medicines agency,, 2013, 27june ema/529295/2013,
[6]
us fda chemistry review: aubagio (teriflunomide) tablets, sanofi-aventis., 2013.
[7]
centre for drug evaluation and research, application number: 202992 orig1s000 chemistry review(s). ondqa division director’s memo, nda 202-992, 05-jun-12, 2013.
[8]
(z)-2-cyano-3-hydroxy-but-2-enoicacid-(4’-trifluormethylphenyl)-amide tablet formulations with im-proved stability, us patent no. us 8802735 b2, 2014.
[9]
european pharmacopoeia 7.0. volume 1. european pharmacopoeia convention, 2011. leflunomide, , 2011, 1, 2345- 2346.
[10]
Parekh, J.M.; Vaghela, R.N.; Sutariya, D.K.; Sanyal, M.; Yadav, M.; Shrivastav, P.S. Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2010, 878(24), 2217-2225.
[PMID: 20643586]
[11]
Rakhila, H.; Rozek, T.; Hopkins, A.; Proudman, S.; Cleland, L.; James, M.; Wiese, M. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. J. Pharm. Biomed. Anal., 2011, 55(2), 325-331.
[PMID: 21349677]
[12]
Saini, B.; Bansal, G. Isolation and characterization of a degradation product in leflunomide and a validated selective stability-indicating HPLC-UV method for their quantification. J. Pharm. Anal., 2015, 5(3), 207-212.
[PMID: 29403933]
[13]
Bhavya, M.; Pravin, P.; Yatin, G. Development and validation of stability indicating RP-HPLC method for estimation of teriflunomide in active pharmaceutical ingredient. Pharma Innovotion Journal, 2017, 6(9), 440-449.
[14]
Nukendra, P.N.; Venkata, N.R.; Srinivasu, N. Quality-by-Design based development and validation of a stability-indicating UPLC method for quantification of teriflunomide in the Presence of degradation products and its application to In-vitro dissolution. J. Liq. Chromatogr. Relat. Technol., 2017, 40, 517-527.
[15]
ich, q1a (r2). stability testing of new drug substances and products; in proceedings of the international conference on harmonization; ifpma, geneva,, . 2003.
[16]
ich, q2 (r1). validation of analytical procedures: text and methodology. international conference on harmonization of technical requirements for registration of pharmaceuticals, ich harmonized tripartite guideline, 2005 november.
[17]
ich, q1b. stability testing: photostability testing of new drug substances and products; in proceedings of the interna-tional conference on harmonization. ifpma, geneva,, 2003.

Rights & Permissions Print Cite
Article Metrics
24
© 2024 Bentham Science Publishers | Privacy Policy